The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose disposal rate () and hepatic glucose output (HGO) were a...
Saved in:
Main Authors: | Kristina Wallenius, Ann Kjellstedt, Pia Thalén, Lars Löfgren, Nicholas D. Oakes |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2013/305347 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01) -
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
by: Tamotsu Tsukahara
Published: (2012-01-01) -
PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01) -
PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
by: Sarawin Harnchoowong, et al.
Published: (2017-01-01) -
The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
by: Lena Serghides
Published: (2012-01-01)